← Back to Home

EU Experts Back Expanded RSV Prevention Use for Enflonsia in Children Still at High Risk in Their Second Season

Some young children continue to face the threat of severe disease after their first RSV season. EU experts have recommended extending the preventive use of clesrovimab to children up to 24 months of age who remain at high risk in their second season, with final approval still pending a European Commission decision.

By SURL BioNews

For some young children with chronic lung disease or congenital heart disease, the threat of respiratory syncytial virus (RSV) does not disappear when their first season ends. For these children, who remain vulnerable to severe disease, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has supported expanding the use of the preventive antibody Enflonsia (clesrovimab), extending protection into a second RSV season.

Merck announced on November 13 that the recommended additional indication covers children up to 24 months of age who remain at increased risk of severe RSV disease during their second season, for the prevention of RSV lower respiratory tract disease. EMA’s November meeting summary, published the same day, also listed Enflonsia among the positive recommendations for indication extensions and explicitly noted that a European Commission decision was still pending. The company expects a final decision within two months.

This expansion builds on the existing preventive use in infants. Enflonsia is a long-acting monoclonal antibody that provides passive immunity by directly supplying antibodies. According to the company’s announcement, the EU approved it in April 2026 for infants during their first RSV season. This review shifts the focus to children who are growing older but still need protection because of underlying health conditions; it does not include all children under two years of age.

The data supporting this recommendation come from the Phase 3 SMART trial. During the first season, high-risk infants were randomized to receive either clesrovimab or monthly palivizumab. In the second season, 276 eligible young children received an additional dose of clesrovimab. According to data released by Merck, approximately 99% of these second-season participants had chronic lung disease or congenital heart disease, indicating that the evidence comes primarily from specific groups of high-risk children.

The study design also defines the limits of interpretation: treatment during the second season was open-label, so the randomized controlled conditions of the first season cannot be directly carried over to infer superiority over other preventive approaches. Although the company’s announcement described the trial framework and related publications, it did not provide specific figures for reductions in the risk of disease or hospitalization during the second season. The benefits of the additional indication therefore should not be quantified solely on the basis of this regulatory announcement.

An expert review milestone has now been passed. If the European Commission approves the expansion, Enflonsia’s preventive use in the EU will cover young children who remain vulnerable during their second season; the actual eligibility criteria will depend on the final approved terms. The significance of this development lies in bringing RSV prevention into closer alignment with children’s continuing risks, rather than defining it solely by whether they have completed their first season.

References

  1. Merck
  2. European Medicines Agency